We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rosetta Genomics Ltd (CE) | USOTC:ROSGQ | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0001 | 0.00 | 01:00:00 |
Record Quarterly Clinical Testing Revenues of $2.6 million
Conference call begins today at 10:00 a.m. Eastern time
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three months ended March 31, 2016.
Recent developments include:
Management Commentary
“We are especially pleased to report record quarterly clinical testing revenues as it demonstrates the progress we have made in expanding our molecular diagnostics test menu, selling our clinical testing products and improving collections,” said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “Throughout the first quarter we completed the revamping of our sales force and invested in our billing and collections department. The results are reflected in our growing revenue and expanding customer base, as well as in improved collections. Further, these changes position us to drive revenue growth throughout the balance of the year and beyond.
“The commercial launch of RosettaGX Reveal continues to be a prime focus for our team. We expect the positive performance data from our blinded validation study to be published in a peer-reviewed journal in the coming weeks. These data demonstrate exceptional performance and we anticipate that a journal publication will strongly support our reimbursement and sales efforts. In addition, our revamped sales team has been able to use RosettaGX Reveal to access new accounts to promote not only our exceptional thyroid offering, but also to promote our urologic cancer and solid tumor product lines. Since the beginning of the year, these promotional efforts resulted in the acquisition of over 30 thyroid customer accounts and over 60 new customer accounts for our urology and solid tumor businesses.
“Our work for the balance of the year will continue to focus on driving revenue growth in both our base business as well as with our new products, such as RosettaGX Reveal, expanding reimbursement, improving collections and advancing our clinical development programs, which should position us to achieve a number of important milestones that will enhance shareholder value,” concluded Mr. Berlin.
First Quarter Financial Results
Please note that the pro forma comparisons below are meant to provide a comparison as if the PersonalizeDx acquisition occurred on January 1, 2015. The actual acquisition date was April 13, 2015.
Balance Sheet Highlights
As of March 31, 2016, Rosetta Genomics had cash, cash equivalents, restricted cash and short-term bank deposits of $12.6 million compared with $13.6 million as of December 31, 2015. The Company used approximately $2.6 million in cash to fund operations during the first quarter of 2016, and collected approximately $2.7 million in cash from its clinical testing services in addition to $1.6 million in cash receipts from a licensing deal signed in December 2015. Based on the Company’s current operations and plans, which include a cost-reduction plan should it be unable to raise sufficient additional capital, if necessary, Rosetta Genomics expects its current cash position will fund operations for at least the next 12 months.
Conference Call
Rosetta Genomics management will host a conference call today beginning at 10:00 a.m. Eastern time to provide an update on the Company’s business and answer questions. Individuals interested in listening to the conference call may do so by dialing (866) 239-5859, or for international callers (702) 495-1913. The conference ID number is 12008886. The call is also being webcast, and can be accessed on the investor relations section of the Company’s website at www.rosettagx.com.
A telephone replay will be available through May 29, 2016 by dialing (855) 859-2056 or for international callers (404) 537-3406, and entering the conference ID number 12008886. The webcast will be available on the Company’s website for 30 days.
Use of Non-GAAP Financial Measures
This press release contains certain non-GAAP financial measures. A "non-GAAP financial measure" refers to a numerical measure of historical or future financial performance, financial position or cash flows that excludes (or includes) amounts that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in the financial statements. In this news release, Rosetta provides non-GAAP pro forma revenues and non-GAAP net loss as additional information relating to its operating results. The presentation of this additional information is not meant to be considered in isolation or as a substitute for revenues, net loss or net loss per share prepared in accordance with GAAP.
Pursuant to the requirements of Regulation G promulgated by the Securities and Exchange Commission, the Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release and related conference call or webcast to the most directly comparable financial measure prepared in accordance with GAAP. This reconciliation is presented in the tables below under the heading "Reconciliation of GAAP to Non-GAAP Consolidated Statement of Operation." Investors are encouraged to review these reconciliations to ensure they have a thorough understanding of the reported non-GAAP financial measures and their most directly comparable GAAP financial measures.
Management uses these non-GAAP measures for internal reporting and forecasting purposes. The Company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP financial measures provide useful information to certain investors and financial analysts for comparison across accounting periods not influenced by certain non-cash items that are not used by management when evaluating the Company's historical and prospective financial performance.
About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. In addition, the Company offers core FISH, IHC and PCR-based testing capabilities in Pathology, Oncology and Urology that provide additional content and platforms that complement Rosetta’s microRNA and Next-Gen Sequencing offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of indeterminate thyroid FNA smears, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs. For more information visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future expectations, plans and prospects including, but not limited to statements that the changes in our sales force and billing and collections department position us to drive revenue growth throughout the balance of the year and beyond; that data from our blinded validation study for RosettaGX Reveal™ will be published in a peer-reviewed journal in the coming weeks and that such publication will support our reimbursement and sales efforts; and that work for the balance of the year will position us to achieve a number of important milestones that will enhance shareholder value; and that our cash, cash equivalents, restricted cash and short-term bank deposits will be sufficient to fund operations for at least the next 12 months, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
March 31, December 31, 2016 2015 Unaudited ASSETS CURRENT ASSETS: Cash and cash equivalents $ 11,901 $ 12,447 Short-term bank deposits and restricted cash 602 1,098 Trade receivables, net 3,132 3,633 Other accounts receivable and prepaid expenses 674 2,192Total current assets
16,309 19,370 LONG TERM ASSETS: Property and equipment, net 2,867 2,975 Restricted bank deposit and other long-term receivables 84 78Total long term assets
2,951 3,053Total assets
$ 19,260 $ 22,423CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share data)
March 31, December 31, 2016 2015 Unaudited LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables $ 1,304 $ 1,070 Other accounts payables and accruals 2,143 1,733Total current liabilities
3,447 2,803 COMMITMENTS AND CONTINGENT LIABILITIES SHAREHOLDERS EQUITY: Share capital:Ordinary Shares of NIS 0.6 par value: 60,000,000 shares authorized at March 31, 2016 and December 31, 2015; 20,856,045 and 20,518,794 shares issued at March 31, 2016 and December 31, 2015, respectively; 20,852,787 and 20,515,536 shares outstanding at March 31, 2016 and December 31, 2015, respectively
3,245 3,194 Additional paid-in capital 156,875 156,696 Accumulated deficit (144,307 ) (140,270 )Total shareholders' equity
15,813 19,620Total liabilities and shareholders' equity
$ 19,260 $ 22,423CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS
U.S. dollars in thousands (except share and per share data)
Three months endedMarch 31,
2016 2015 Unaudited Revenues $ 2,603 $ 321 Cost of revenues 1,658 352 Gross profit (loss) 945 (31 ) Operating expenses: Research and development, net 842 748 Sales, marketing and business development 1,897 1,597 General and administrative 2,213 1,411 Total operating expenses 4,952 3,756 Operating loss 4,007 3,787 Financial expenses, net 24 76 Tax expense 6 5 Net loss $ 4,037 $ 3,868Basic and diluted net loss per ordinary share attributable to Rosetta Genomics' shareholders
$ 0.20 $ 0.30Weighted average number of ordinary shares used to compute basic and diluted net loss per ordinary share
20,650,323 12,767,221 Quarter ended March 31, 2015USD in thousands
(Unaudited) GAAP revenues $ 321Additional revenues from PersonalizeDx for non-consolidated period of January 1, 2015 - April 12, 2015
1,734 Pro forma revenues $ 2,055 Quarter ended March 31, 2015USD in thousands
(Unaudited) GAAP revenues for solid tumor testing services $ 321Additional revenues from PersonalizeDx for non-consolidated period of January 1, 2015 - April 12, 2015
432 Pro forma revenues for solid tumor testing services $ 753 Quarter ended March 31, 2015USD in thousands
(Unaudited) GAAP revenues for urologic cancer testing services $-
Additional revenues from PersonalizeDx for non-consolidated period of January 1, 2015 - April 12, 2015
1,302 Pro forma revenues for urologic cancer testing services $ 1,302 Quarter ended March 31, 2016 2015USD in thousands
(Unaudited) (Unaudited) Net loss $ 4,037 $ 3,868 Share-based compensation 230 276non-GAAP net loss
$ 3,807 $ 3,592 Quarter ended March 31, 2016 2015Basic and diluted per share data
(Unaudited) (Unaudited) Net loss $ 0.195 $ 0.303 Share-based compensation $ 0.011 $ 0.022 non-GAAP net loss $ 0.184 $ 0.281Weighted average number of Ordinary shares used to
compute basic and diluted net loss per Ordinary share 20,650,323 12,767,221
View source version on businesswire.com: http://www.businesswire.com/news/home/20160519005354/en/
Rosetta Genomics:Ken Berlin, 267-298-1159President & CEOinvestors@rosettagx.comorRosetta Genomics Investors:LHAAnne Marie Fields, 212-838-3777afields@lhai.com
1 Year Rosetta Genomics (CE) Chart |
1 Month Rosetta Genomics (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions